{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:20:03Z","timestamp":1784557203178,"version":"3.55.0"},"reference-count":70,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["joe.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>\n                    Antipsychotics (APs) are linked to diabetes, even without weight gain. Whether anti-diabetic drugs are efficacious in reversing the direct effects of APs on glucose pathways is largely undetermined. We tested two metformin (Met) doses to prevent impairments seen following a dose of olanzapine (Ola) (3\u200amg\/kg); glucokinetics were measured using the hyperinsulinemic-euglycemic clamp (HIEC). Met (150\u200amg\/kg;\n                    <jats:italic>n<\/jats:italic>\n                    =13, or 400\u200amg\/kg;\n                    <jats:italic>n<\/jats:italic>\n                    =11) or vehicle (Veh) (\n                    <jats:italic>n<\/jats:italic>\n                    =11) was administered through gavage preceding an overnight fast, followed by a second dose prior to the HIEC. Eleven additional animals were gavaged with Veh and received a Veh injection during the HIEC (Veh\/Veh); all others received Ola. Basal glucose was similar across treatment groups. The Met 400 group had significantly greater glucose appearance (R\n                    <jats:sub>a<\/jats:sub>\n                    ) in the basal period (i.e., before Ola, or hyperinsulinemia) vs other groups. During hyperinsulinemia, glucose infusion rate (GINF) to maintain euglycemia (reflective of whole-body insulin sensitivity) was higher in Veh\/Veh vs other groups. Met 150\/Ola animals demonstrated increased GINF relative to Veh\/Ola during early time points of the HIEC. Glucose utilization during hyperinsulinemia, relative to basal conditions, was significantly higher in Veh\/Veh vs other groups. The change in hepatic glucose production (HGP) from basal to hyperinsulinemia demonstrated significantly greater decreases in Veh\/Veh and Met 150\/Ola groups vs Veh\/Ola. Given the increase in basal R\n                    <jats:sub>a<\/jats:sub>\n                    with Met 400, we measured serum lactate (substrate for HGP), finding increased levels in Met 400 vs Veh and Met 150. In conclusion, Met attenuates hepatic insulin resistance observed with acute Ola administration, but fails to improve peripheral insulin resistance. Use of supra-therapeutic doses of Met may mask metabolic benefits by increasing lactate.\n                  <\/jats:p>","DOI":"10.1530\/joe-15-0074","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T21:23:30Z","timestamp":1441142610000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":27,"title":["Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance"],"prefix":"10.1530","volume":"227","author":[{"given":"Gary J","family":"Remington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araba","family":"Chintoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Guenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohra","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adria","family":"Giacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2015110216231916000_227.2.71.1","unstructured":"Adeneye AA Agbaje EO Olagunju JA 2011 Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats. Indian Journal of Experimental Biology 49 332\u2013338."},{"key":"2015110216231916000_227.2.71.2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.3.862"},{"key":"2015110216231916000_227.2.71.3","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2010.33"},{"key":"2015110216231916000_227.2.71.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022662"},{"key":"2015110216231916000_227.2.71.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S014"},{"key":"2015110216231916000_227.2.71.6","doi-asserted-by":"crossref","unstructured":"Arman S Sadramely MR Nadi M Koleini N 2008 A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal 29 1130\u20131134.","DOI":"10.1016\/S0084-3970(08)70618-2"},{"key":"2015110216231916000_227.2.71.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2006.06.016"},{"key":"2015110216231916000_227.2.71.8","unstructured":"Canadian Psychiatric Association Clinical practice guidelines. Treatment of schizophrenia Canadian Journal of Psychiatry 50 2005 7S\u201357S."},{"key":"2015110216231916000_227.2.71.9","doi-asserted-by":"crossref","unstructured":"Baptista T Martinez J Lacruz A Rangel N Beaulieu S Serrano A Arape Y Martinez M de Mendoza S Teneud L 2006 Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Canadian Journal of Psychiatry 51 192\u2013196.","DOI":"10.1177\/070674370605100310"},{"key":"2015110216231916000_227.2.71.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.03.029"},{"key":"2015110216231916000_227.2.71.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(01)01225-5"},{"key":"2015110216231916000_227.2.71.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00612-3"},{"key":"2015110216231916000_227.2.71.13","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.110140"},{"key":"2015110216231916000_227.2.71.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2013.10.006"},{"key":"2015110216231916000_227.2.71.15","unstructured":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Booth G Cheng AY 2013 Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 37 (Suppl 1) S1\u2013S3. (doi:10.1016\/j.jcjd.2013.01.009)"},{"key":"2015110216231916000_227.2.71.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.05.007"},{"key":"2015110216231916000_227.2.71.17","doi-asserted-by":"crossref","unstructured":"Chen CH Huang MC Kao CF Lin SK Kuo PH Chiu CC Lu ML 2013 Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 74 e424\u2013e430. (doi:10.4088\/JCP.12m08186)","DOI":"10.4088\/JCP.12m08186"},{"key":"2015110216231916000_227.2.71.18","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318184b4c5"},{"key":"2015110216231916000_227.2.71.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.12.012"},{"key":"2015110216231916000_227.2.71.20","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.12.3258"},{"key":"2015110216231916000_227.2.71.21","doi-asserted-by":"publisher","DOI":"10.1021\/ja074871l"},{"key":"2015110216231916000_227.2.71.22","doi-asserted-by":"publisher","DOI":"10.1186\/1745-0179-2-14"},{"key":"2015110216231916000_227.2.71.23","doi-asserted-by":"crossref","unstructured":"De Hert M Peuskens J van Winkel R 2009 Mortality in patients with schizophrenia. Lancet 374 1591; author reply 1592\u20131593. (doi:10.1016\/S0140-6736(09)61942-5)","DOI":"10.1016\/S0140-6736(09)61942-5"},{"key":"2015110216231916000_227.2.71.24","doi-asserted-by":"crossref","unstructured":"Ebdrup BH Knop FK Madsen A Mortensen HB Sogaard B Holst JJ Szecsi PB Lublin H 2014 Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. Journal of Clinical Psychiatry 75 e899\u2013e905. (doi:10.4088\/JCP.13m08820)","DOI":"10.4088\/JCP.13m08820"},{"key":"2015110216231916000_227.2.71.25","doi-asserted-by":"publisher","DOI":"10.2337\/diab.36.8.914"},{"key":"2015110216231916000_227.2.71.26","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.22.2631"},{"key":"2015110216231916000_227.2.71.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.08.010"},{"key":"2015110216231916000_227.2.71.28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.58.4.536"},{"key":"2015110216231916000_227.2.71.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-2982-3"},{"key":"2015110216231916000_227.2.71.30","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31829e8333"},{"key":"2015110216231916000_227.2.71.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.07.011"},{"key":"2015110216231916000_227.2.71.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2007.11.017"},{"key":"2015110216231916000_227.2.71.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2009.12.015"},{"key":"2015110216231916000_227.2.71.34","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.1.19"},{"key":"2015110216231916000_227.2.71.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01325.x"},{"key":"2015110216231916000_227.2.71.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.02.007"},{"key":"2015110216231916000_227.2.71.37","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2010.71"},{"key":"2015110216231916000_227.2.71.38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301209"},{"key":"2015110216231916000_227.2.71.39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.58.2.270"},{"key":"2015110216231916000_227.2.71.40","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12010127"},{"key":"2015110216231916000_227.2.71.41","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046987"},{"key":"2015110216231916000_227.2.71.42","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.12.2072"},{"key":"2015110216231916000_227.2.71.43","doi-asserted-by":"publisher","DOI":"10.1097\/01.nmd.0000221177.51089.7d"},{"key":"2015110216231916000_227.2.71.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.05.011"},{"key":"2015110216231916000_227.2.71.45","doi-asserted-by":"publisher","DOI":"10.1210\/en.133.1.304"},{"key":"2015110216231916000_227.2.71.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.07.014"},{"key":"2015110216231916000_227.2.71.47","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519010-00001"},{"key":"2015110216231916000_227.2.71.48","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.4.337"},{"key":"2015110216231916000_227.2.71.49","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2003.00263.x"},{"key":"2015110216231916000_227.2.71.50","doi-asserted-by":"publisher","DOI":"10.1042\/bj3480607"},{"key":"2015110216231916000_227.2.71.51","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00006"},{"key":"2015110216231916000_227.2.71.52","doi-asserted-by":"publisher","DOI":"10.2337\/diab.46.9.1406"},{"key":"2015110216231916000_227.2.71.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.11.010"},{"key":"2015110216231916000_227.2.71.54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301541"},{"key":"2015110216231916000_227.2.71.55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30558"},{"key":"2015110216231916000_227.2.71.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.07.011"},{"key":"2015110216231916000_227.2.71.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.10.023"},{"key":"2015110216231916000_227.2.71.58","doi-asserted-by":"crossref","unstructured":"Stetten D Jr Welt ID Ingle DJ Morley EH 1951 Rates of glucose production and oxidation in normal and diabetic rats. Journal of Biological Chemistry 192 817\u2013830.","DOI":"10.1016\/S0021-9258(19)77804-1"},{"key":"2015110216231916000_227.2.71.59","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.2002.03644.x"},{"key":"2015110216231916000_227.2.71.60","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0430"},{"key":"2015110216231916000_227.2.71.61","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1815"},{"key":"2015110216231916000_227.2.71.62","doi-asserted-by":"crossref","unstructured":"Vidarsdottir S Vlug P Roelfsema F Frolich M Pijl H 2010b Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. Journal of Clinical Psychiatry 71 1205\u20131211. (doi:10.4088\/JCP.08m04654yel)","DOI":"10.4088\/JCP.08m04654yel"},{"key":"2015110216231916000_227.2.71.63","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.109.074674"},{"key":"2015110216231916000_227.2.71.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.02.021"},{"key":"2015110216231916000_227.2.71.65","doi-asserted-by":"publisher","DOI":"10.1080\/09595239996734"},{"key":"2015110216231916000_227.2.71.66","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07010079"},{"key":"2015110216231916000_227.2.71.67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2007.56-b"},{"key":"2015110216231916000_227.2.71.68","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.11091432"},{"key":"2015110216231916000_227.2.71.69","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.064964"},{"key":"2015110216231916000_227.2.71.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.09.003"}],"container-title":["Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/joe.bioscientifica.com\/view\/journals\/joe\/227\/2\/71.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/joe.bioscientifica.com\/downloadpdf\/journals\/joe\/227\/2\/71.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:54:57Z","timestamp":1784555697000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/joe\/article\/227\/2\/71-81\/22771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,1]]},"references-count":70,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/joe-15-0074","relation":{},"ISSN":["0022-0795","1479-6805"],"issn-type":[{"value":"0022-0795","type":"print"},{"value":"1479-6805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,1]]}}}